688520 神州细胞
已收盘 10-12 15:00:00
资讯
新帖
简况
神州细胞（688520）10月9日主力资金净买入1338.72万元
证券之星 · 10-10 08:16
神州细胞（688520）10月9日主力资金净买入1338.72万元
神州细胞集团公司（688520）9月24日主力资金净卖出1231.62万元
证券之星 · 09-25
神州细胞集团公司（688520）9月24日主力资金净卖出1231.62万元
神州细胞（688520.SH）A+H最新进展
中金财经 · 09-20
神州细胞（688520.SH）A+H最新进展
每周股票复盘：神州细胞集团公司（688520）股东拟合计减持不超0.94%股份
证券之星 · 09-20
每周股票复盘：神州细胞集团公司（688520）股东拟合计减持不超0.94%股份
神州细胞：9月16日召开业绩说明会，投资者参与
证券之星 · 09-17
神州细胞：9月16日召开业绩说明会，投资者参与
神州细胞(688520.SH)股东拟合计减持不超0.94%股份
智通财经 · 09-13
神州细胞(688520.SH)股东拟合计减持不超0.94%股份
神州细胞（688520）披露2026年半年度报告，8月31日股价下跌3.73%
证券之星 · 08-31
神州细胞（688520）披露2026年半年度报告，8月31日股价下跌3.73%
神州细胞（688520）2026年中报简析：净利润同比下降982.86%，三费占比上升明显
证券之星 · 08-30
神州细胞（688520）2026年中报简析：净利润同比下降982.86%，三费占比上升明显
图解神州细胞中报：第二季度单季净利润同比下降94.80%
证券之星 · 08-29
图解神州细胞中报：第二季度单季净利润同比下降94.80%
每周股票复盘：神州细胞（688520）SCTA02A获乙肝临床试验批准
证券之星 · 08-23
每周股票复盘：神州细胞（688520）SCTA02A获乙肝临床试验批准
神州细胞最新公告：控股子公司产品SCTA02A获药物临床试验批准
证券之星 · 08-19
神州细胞最新公告：控股子公司产品SCTA02A获药物临床试验批准
神州细胞冲刺港股IPO：集采重创“现金奶牛”，盈亏反复造血乏力，烧钱不止负债攀升
证券之星 · 06-24
神州细胞冲刺港股IPO：集采重创“现金奶牛”，盈亏反复造血乏力，烧钱不止负债攀升
【机构调研记录】华夏基金调研神州细胞、瑞迈特等6只个股（附名单）
证券之星 · 06-01
【机构调研记录】华夏基金调研神州细胞、瑞迈特等6只个股（附名单）
【IPO速递】赴港！神州细胞（688520.SH）冲刺“A+H”，最大隐忧是什么？
IPO解码 · 05-27
【IPO速递】赴港！神州细胞（688520.SH）冲刺“A+H”，最大隐忧是什么？
神州细胞递表港交所：核心收入高度依赖单品，造血能力与出海野望“面临考验”
蓝鲸财经 · 05-25
神州细胞递表港交所：核心收入高度依赖单品，造血能力与出海野望“面临考验”
神州细胞（688520）披露向港交所递交H股发行及上市申请，5月25日股价下跌2.09%
证券之星 · 05-25
神州细胞（688520）披露向港交所递交H股发行及上市申请，5月25日股价下跌2.09%
神州细胞，递交香港IPO招股书，中信证券独家保荐
瑞恩资本 · 05-24
神州细胞，递交香港IPO招股书，中信证券独家保荐
每周股票复盘：神州细胞（688520）递交H股上市申请
证券之星 · 05-24
每周股票复盘：神州细胞（688520）递交H股上市申请
神州细胞冲刺港股：第一季营收3亿同比降38% 亏1.8亿
雷递网 · 05-23
神州细胞冲刺港股：第一季营收3亿同比降38% 亏1.8亿
新股消息 | 神州细胞(688520.SH)递表港交所
智通财经 · 05-23
新股消息 | 神州细胞(688520.SH)递表港交所
加载更多
公司概况
公司名称：
北京神州细胞生物技术集团股份公司
所属行业：
医药制造业
上市日期：
2020-06-22
主营业务：
北京神州细胞生物技术集团股份公司的主营业务是治疗性抗体、重组蛋白及疫苗的研发、生产与商业化。公司的主要产品是重组蛋白药物、抗体药物。
发行价格：
25.64
{"stockData":{"symbol":"688520","market":"SH","secType":"STK","nameCN":"神州细胞","latestPrice":34.87,"timestamp":1791788400000,"preClose":36.22,"halted":0,"volume":2469406,"delay":0,"changeRate":-0.0373,"floatShares":445000000,"shares":470000000,"eps":-1.9067,"marketStatus":"已收盘","change":-1.35,"latestTime":"10-12 15:00:00","open":36.34,"high":36.47,"low":34.77,"amount":86904900,"amplitude":0.0469,"askPrice":34.88,"askSize":54,"bidPrice":34.87,"bidSize":2,"shortable":0,"etf":0,"ttmEps":-1.9067,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1791855000000},"marketStatusCode":5,"adr":0,"adjPreClose":36.22,"symbolType":"stock_kcb","openAndCloseTimeList":[[1791768600000,1791775800000],[1791781200000,1791788400000]],"highLimit":39.84,"lowLimit":32.6,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":470335714,"isCdr":false,"pbRate":-110.69,"roa":"--","roe":"--","epsLYR":-1.32,"committee":-0.099526,"marketValue":16401000000,"turnoverRate":0.0055,"status":1,"afterMarket":{"amount":0,"volume":0,"close":34.87,"buyVolume":2670,"sellVolume":0,"time":1791790437746,"indexStatus":"已收盘 10-12 15:30:00","preClose":36.22},"floatMarketCap":15529000000},"requestUrl":"/m/hq/s/688520","defaultTab":"news","newsList":[{"id":"2674867023","title":"神州细胞（688520）10月9日主力资金净买入1338.72万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2674867023","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674867023?lang=zh_cn&edition=full","pubTime":"2026-10-10 08:16","pubTimestamp":1791591371,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年10月9日收盘，神州细胞报收于36.22元，上涨4.38%，换手率0.87%，成交量3.89万手，成交额1.38亿元。近5日资金流向一览见下表：神州细胞融资融券信息显示，融资方面，当日融资买入998.95万元，融资偿还1309.74万元，融资净偿还310.78万元。神州细胞主营业务：专注于恶性肿瘤、自身免疫性疾病、感染性疾病和遗传病等多个治疗和预防领域的生物药产品研发和产业化。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101000003832.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688520"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670194164","title":"神州细胞集团公司（688520）9月24日主力资金净卖出1231.62万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2670194164","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670194164?lang=zh_cn&edition=full","pubTime":"2026-09-25 08:31","pubTimestamp":1790296314,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年9月24日收盘，神州细胞集团公司报收于35.75元，下跌3.95%，换手率0.86%，成交量3.82万手，成交额1.39亿元。近5日资金流向一览见下表：神州细胞集团公司融资融券信息显示，融资方面，当日融资买入881.05万元，融资偿还722.07万元，融资净买入158.98万元。神州细胞集团公司主营业务：专注于恶性肿瘤、自身免疫性疾病、感染性疾病和遗传病等多个治疗和预防领域的生物药产品研发和产业化。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092500005273.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688520","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668690758","title":"神州细胞（688520.SH）A+H最新进展","url":"https://stock-news.laohu8.com/highlight/detail?id=2668690758","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668690758?lang=zh_cn&edition=full","pubTime":"2026-09-20 10:30","pubTimestamp":1789871401,"startTime":"0","endTime":"0","summary":"二、请逐项列示本次发行募集资金用于境内外投资项目的具体金额及比例，并说明相关审批、核准或备案程序履行情况，如在履行相关程序过程中请出具募集资金全部调回境内的承诺。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20260920/32375467.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0239","688520"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668390672","title":"每周股票复盘：神州细胞集团公司（688520）股东拟合计减持不超0.94%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2668390672","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668390672?lang=zh_cn&edition=full","pubTime":"2026-09-20 01:35","pubTimestamp":1789839311,"startTime":"0","endTime":"0","summary":"截至2026年9月18日收盘，神州细胞集团公司报收于33.71元，较上周的32.41元上涨4.01%。本周，神州细胞集团公司9月18日盘中最高价报33.96元。本周关注点公司公告汇总：神州安元等股东拟合计减持不超过4,394,500股，占公司总股本不超过0.94%。上述股东因个人资金需求，计划通过集中竞价方式合计减持不超过4,394,500股，占公司总股本不超过0.94%，减持期间为2026年10月13日至2027年1月12日。公司控股股东、实际控制人承诺不参与本次减持。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092000000315.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688520"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668090967","title":"神州细胞：9月16日召开业绩说明会，投资者参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2668090967","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668090967?lang=zh_cn&edition=full","pubTime":"2026-09-17 21:03","pubTimestamp":1789650184,"startTime":"0","endTime":"0","summary":"证券之星消息，2026年9月17日神州细胞发布公告称公司于2026年9月16日召开业绩说明会。融资融券数据显示该股近3个月融资净流出934.52万，融资余额减少；融券净流入123.0万，融券余额增加。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091700034796.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688520","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667568970","title":"神州细胞(688520.SH)股东拟合计减持不超0.94%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2667568970","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667568970?lang=zh_cn&edition=full","pubTime":"2026-09-13 15:46","pubTimestamp":1789285585,"startTime":"0","endTime":"0","summary":"智通财经APP讯，神州细胞(688520.SH)发布公告，公司于近日收到股东暨员工持股平台神州安元、神州安恒、神州安成、神州安弘送达的《关于股份减持计划的告知函》，神州安元、神州安恒、神州安成、神州安弘因个人资金需求，计划通过集中竞价方式减持其持有的公司股份，合计不超过439.45万股(含本数)，占公司总股本不超过0.94%，减持期间为公告披露之日起15个交易日后的3个月内。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495347.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688520","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663507122","title":"神州细胞（688520）披露2026年半年度报告，8月31日股价下跌3.73%","url":"https://stock-news.laohu8.com/highlight/detail?id=2663507122","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663507122?lang=zh_cn&edition=full","pubTime":"2026-08-31 18:03","pubTimestamp":1788170618,"startTime":"0","endTime":"0","summary":"截至2026年8月31日收盘，神州细胞报收于35.07元，较前一交易日下跌3.73%，最新总市值为164.95亿元。该股当日开盘36.23元，最高36.23元，最低34.85元，成交额达1.08亿元，换手率为0.69%。公司于近日披露《2026年半年度报告》。公告显示，截至报告期末，公司总资产为3,961,598,391.90元，较上年度末增长3.59%；归属于上市公司股东的净资产为633,391,841.97元，较上年度末增长393.78%。研发投入占营业收入的比例为58.89%，较上年同期增加18.98个百分点。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083100025865.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688520"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663484610","title":"神州细胞（688520）2026年中报简析：净利润同比下降982.86%，三费占比上升明显","url":"https://stock-news.laohu8.com/highlight/detail?id=2663484610","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663484610?lang=zh_cn&edition=full","pubTime":"2026-08-30 06:17","pubTimestamp":1788041849,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期神州细胞发布2026年中报。截至本报告期末，公司营业总收入6.59亿元，同比下降32.16%，归母净利润-3.66亿元，同比下降982.86%。按单季度数据看，第二季度营业总收入3.36亿元，同比下降25.67%，第二季度归母净利润-1.9亿元，同比下降94.8%。本报告期神州细胞三费占比上升明显，财务费用、销售费用和管理费用总和占总营收同比增幅达37.06%。本文数据来源于神州细胞2026年中报，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083000002400.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688520"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663180590","title":"图解神州细胞中报：第二季度单季净利润同比下降94.80%","url":"https://stock-news.laohu8.com/highlight/detail?id=2663180590","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663180590?lang=zh_cn&edition=full","pubTime":"2026-08-29 03:05","pubTimestamp":1787943921,"startTime":"0","endTime":"0","summary":"证券之星消息，神州细胞2026年中报显示，上半年度公司主营收入6.59亿元，同比下降32.16%；归母净利润-3.66亿元，同比下降982.86%；扣非净利润-3.16亿元，同比下降775.87%；其中2026年第二季度，公司单季度主营收入3.36亿元，同比下降25.67%；单季度归母净利润-1.9亿元，同比下降94.8%；单季度扣非净利润-1.69亿元，同比下降182.74%；负债率83.84%，投资收益126.28万元，财务费用3571.32万元，毛利率90.31%。财报数据概要请见下图:本文数据来源于神州细胞2026年中报，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082900006528.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688520"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661321122","title":"每周股票复盘：神州细胞（688520）SCTA02A获乙肝临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2661321122","media":"证券之星","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661321122?lang=zh_cn&edition=full","pubTime":"2026-08-23 02:31","pubTimestamp":1787423469,"startTime":"0","endTime":"0","summary":"截至2026年8月21日收盘，神州细胞报收于37.89元，较上周的39.4元下跌3.83%。本周，神州细胞8月20日盘中最高价报43.55元。SCTA02A为重组抗HBsAg单克隆抗体注射液，当前乙肝功能性治愈手段有限，临床需求较高。神州细胞控股子公司神州细胞工程有限公司获国家药品监督管理局批准，其自主研发的SCTB10注射液开展A型血友病I/II期临床研究。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082300000456.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688520","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660044429","title":"神州细胞最新公告：控股子公司产品SCTA02A获药物临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2660044429","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660044429?lang=zh_cn&edition=full","pubTime":"2026-08-19 18:22","pubTimestamp":1787134959,"startTime":"0","endTime":"0","summary":"神州细胞(688520.SH)公告称，公司控股子公司神州细胞工程收到国家药监局核准签发的《药物临床试验批准通知书》，同意自主研发产品SCTA02A注射液开展慢性乙型肝炎的临床试验。该产品是公司以功能性治愈慢性乙肝为目标设计的产品组合中首个获批临床的品种，本次获批开展I期临床试验。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081900032307.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688520"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645539860","title":"神州细胞冲刺港股IPO：集采重创“现金奶牛”，盈亏反复造血乏力，烧钱不止负债攀升","url":"https://stock-news.laohu8.com/highlight/detail?id=2645539860","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2645539860?lang=zh_cn&edition=full","pubTime":"2026-06-24 15:11","pubTimestamp":1782285118,"startTime":"0","endTime":"0","summary":"神州细胞2025年经营现金流告负，流动负债缺口进一步扩大。截至2025年12月31日，安佳因已纳入国内20余个省级地区的省际联盟集中采购目录。神州细胞坦言，客户集中度相对较高，失去任何主要客户都可能对业务、经营业绩及财务状况造成不利影响。证券之星注意到，高毛利背后，神州细胞的盈亏反复。神州细胞表示，港股融资旨在打造国际化资本运作平台，拓宽全球资金渠道，增强长期资本实力。截至2025年末，神州细胞","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/SS2026062400022240.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688520","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640598186","title":"【机构调研记录】华夏基金调研神州细胞、瑞迈特等6只个股（附名单）","url":"https://stock-news.laohu8.com/highlight/detail?id=2640598186","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2640598186?lang=zh_cn&edition=full","pubTime":"2026-06-01 08:02","pubTimestamp":1780272136,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及5月29日披露的机构调研信息，华夏基金近期对6家上市公司进行了调研，相关名单如下：1）神州细胞 调研纪要：公司2025年实现营业总收入15.60亿元，同比减少37.91%；归母净利润-5.65亿元。降价及销量下降。同时将公布ZG006在晚期神经内分泌癌、小细胞肺癌等适应症中的多项临床研究数据，部分入选胃肠道癌症专场口头报告。ZG006联合HS-20093治疗广泛期小细胞肺癌的临床试验已获批准。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060100002545.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688520","301367","BK0251","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638092658","title":"【IPO速递】赴港！神州细胞（688520.SH）冲刺“A+H”，最大隐忧是什么？","url":"https://stock-news.laohu8.com/highlight/detail?id=2638092658","media":"IPO解码","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2638092658?lang=zh_cn&edition=full","pubTime":"2026-05-27 16:07","pubTimestamp":1779869220,"startTime":"0","endTime":"0","summary":"近日，来自A股科创板的神州细胞正式向港交所递交招股书，拟在主板挂牌上市，由中信证券担任独家保荐人。值得一提的是，百济神州、恒瑞医药等创新药企已经完成两地布局，如果神州细胞此番成功上市，也将加入“A+H”大军。招股书显示，神州细胞于2020年6月登陆A股科创板，上市以来其股价起起落落，波动巨大，最新市值接近185亿元。神州细胞还有一点值得投资者注意，神州细胞登陆A股后，实控人并未稀释股权，反而主动加码。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/hkzmt/2026-05-27/doc-inhzmayu7896728.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["688520","BK0239","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638553252","title":"神州细胞递表港交所：核心收入高度依赖单品，造血能力与出海野望“面临考验”","url":"https://stock-news.laohu8.com/highlight/detail?id=2638553252","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2638553252?lang=zh_cn&edition=full","pubTime":"2026-05-25 21:41","pubTimestamp":1779716512,"startTime":"0","endTime":"0","summary":"目前来看，在去年以及今年一季度持续陷入大幅亏损后，神州细胞通过定增迅速缓解了现金流压力，短期内没有资金链断裂风险。在常年亏损之下，神州细胞财务压力较大，亟需通过多渠道进行融资。核心收入高度依赖单品翻阅上市申请文件，神州细胞拥有差异化的“硬资产”，且已沉淀出可验证的商业与制造能力。首先，核心收入高度依赖单品，虽然神州细胞目前有多个商业化产品，但目前为止，安佳因是其绝对收入支柱。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1779715232167185685","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["688520","IPOS","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638534612","title":"神州细胞（688520）披露向港交所递交H股发行及上市申请，5月25日股价下跌2.09%","url":"https://stock-news.laohu8.com/highlight/detail?id=2638534612","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2638534612?lang=zh_cn&edition=full","pubTime":"2026-05-25 18:03","pubTimestamp":1779703399,"startTime":"0","endTime":"0","summary":"截至2026年5月25日收盘，神州细胞报收于39.8元，较前一交易日下跌2.09%，最新总市值为187.19亿元。近日，神州细胞发布《关于向香港联交所递交H股发行及上市申请并刊发申请资料的公告》。公告显示，公司已于2026年5月22日向香港联合交易所有限公司递交发行H股并在主板上市的申请，并于同日在港交所网站刊登了申请资料。本次发行上市尚需获得中国证监会、香港证监会及港交所等监管机构批准，存在不确定性。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052500025601.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["HEXmain","688520","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637839309","title":"神州细胞，递交香港IPO招股书，中信证券独家保荐","url":"https://stock-news.laohu8.com/highlight/detail?id=2637839309","media":"瑞恩资本","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2637839309?lang=zh_cn&edition=full","pubTime":"2026-05-24 21:50","pubTimestamp":1779630600,"startTime":"0","endTime":"0","summary":"2026年5月22日，来自北京的A股上市公司北京神州细胞生物技术集团股份公司SINOCELLTECH GROUP LIMITED向港交所递交招股书，拟在香港主板上市。神州细胞，于2020年06月22日在A股上市，截至2026年5月22日收市，其总市值约191亿元人民币。安贝珠上市后即被纳入国家医保药品目录。股东架构招股书显示，神州细胞在上市前的股东架构中，谢良志博士、李翰园女士夫妇，合计持股约70.86%，为控股股东。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-05-24/doc-inhyzkke4103994.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1564","LU1794554557.SGD","688520","BK0276","LU1328615791.USD","LU1580142542.USD","BK0183","LU1064130708.USD","LU1064131003.USD","LU2495084118.USD","BK1147","LU2148510915.USD","BK0012","BK1516","06030","BK0196","LU1997245177.USD","LU0405327148.USD","LU1997245094.SGD","LU0405327494.USD","LU1720050803.USD","LU2289578879.USD","BK0028","BK0188","LU1997244956.HKD","LU1655091616.SGD","600030","BK0239","IPOS","BK1521","LU1255011170.USD","LU1781817850.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637137653","title":"每周股票复盘：神州细胞（688520）递交H股上市申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2637137653","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2637137653?lang=zh_cn&edition=full","pubTime":"2026-05-24 04:41","pubTimestamp":1779568869,"startTime":"0","endTime":"0","summary":"截至2026年5月22日收盘，神州细胞报收于40.65元，较上周的42.1元下跌3.44%。本周，神州细胞5月21日盘中最高价报43.43元。神州细胞当前最新总市值191.19亿元，在生物制品板块市值排名15/51，在两市A股市值排名1156/5206。本周关注点公司公告汇总：神州细胞已向港交所递交H股发行及上市申请。公司不会在境内媒体刊登该资料，相关信息可通过港交所网站查询。本次发行上市尚需获得中国证监会、香港证监会及港交所等监管机构批准，存在不确定性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052400001468.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688520","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637320565","title":"神州细胞冲刺港股：第一季营收3亿同比降38% 亏1.8亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2637320565","media":"雷递网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2637320565?lang=zh_cn&edition=full","pubTime":"2026-05-23 23:00","pubTimestamp":1779548422,"startTime":"0","endTime":"0","summary":"北京神州细胞生物技术集团股份公司（简称：“神州细胞”）日前递交招股书，准备在港交所上市。","market":"hk","thumbnail":"https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20260523/6391517400313277339139051.jpeg","type":0,"news_type":0,"thumbnails":["https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20260523/6391517400313277339139051.jpeg"],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.leinews.com/n33778/detail.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"leinews_highlight","symbols":["688520","VXUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637329912","title":"新股消息 | 神州细胞(688520.SH)递表港交所","url":"https://stock-news.laohu8.com/highlight/detail?id=2637329912","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2637329912?lang=zh_cn&edition=full","pubTime":"2026-05-23 15:06","pubTimestamp":1779519990,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，据港交所5月22日披露，北京神州细胞生物技术集团股份公司(688520.SH)向港交所主板递交上市申请书，中信证券为独家保荐人。据招股书，神州细胞是一家创新型生物制药公司，专注于治疗性抗体、重组蛋白及疫苗的研发、生产及商业化。自2002年成立以来，神州细胞一直致力于自主研发，建立了支持药物发现、临床开发及商业化的端到端开发平台。凭借集成技术平台，该公司已建立涵盖肿瘤、自身免疫、眼科、血友病及疫苗的产品管线。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1445397.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","HEXmain","688520","IPOS"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1791803978467,"stockEarnings":[{"period":"1week","weight":-0.0224},{"period":"1month","weight":0.0647},{"period":"3month","weight":-0.0308},{"period":"6month","weight":-0.1356},{"period":"1year","weight":-0.3576},{"period":"ytd","weight":-0.1637}],"compareEarnings":[{"period":"1week","weight":-0.0074},{"period":"1month","weight":-0.0349},{"period":"3month","weight":-0.0456},{"period":"6month","weight":-0.0433},{"period":"1year","weight":-0.0305},{"period":"ytd","weight":-0.0391}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"北京神州细胞生物技术集团股份公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"11465人(较上一季度减少14.98%)","perCapita":"38843股","listingDate":"2020-06-22","address":"北京市大兴区北京经济技术开发区科创七街31号院5号楼307","registeredCapital":"47033万元","survey":" 北京神州细胞生物技术集团股份公司的主营业务是治疗性抗体、重组蛋白及疫苗的研发、生产与商业化。公司的主要产品是重组蛋白药物、抗体药物。","listedPrice":25.64},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"神州细胞(688520)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供神州细胞(688520)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"神州细胞,688520,神州细胞股票,神州细胞股票老虎,神州细胞股票老虎国际,神州细胞行情,神州细胞股票行情,神州细胞股价,神州细胞股市,神州细胞股票价格,神州细胞股票交易,神州细胞股票购买,神州细胞股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"神州细胞(688520)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供神州细胞(688520)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}